The clinical features, risk factors and outcomes of polyomavirus encephalitis after allogeneic haematological stem cell transplantation
British Journal of Haematology · 2025
DOI: 10.1111/bjh.70105 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Xu-Ying Pei und 15 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Polyomavirus Infections, Encephalitis, Viral. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, Being Nova Program, Beijing Municipal Science & Technology Commission.
Abstract (Originalsprache)
Polyomavirus (PyV) encephalitis is a rare but life‐threatening opportunistic infection linked to progressive multifocal leucoencephalopathy (PML). We analysed 54 patients diagnosed with PyV encephalitis after allogeneic haematopoietic stem cell transplantation (allo‐HSCT) in a 1:4 case–control retrospective cohort study. Median time to diagnosis was 77 days post‐HSCT, with seizures, headache and motor dysfunction as the most common presenting symptoms. PyV‐associated mortality at 6 months and 1 year was 18.5% and 24.2% respectively. BK virus (BKV) and JC virus (JCV) encephalitis showed comparable 3‐year non‐relapse mortality (NRM: 31.5% vs. 25.0%) or overall survival (OS: 61.5% vs. 62.5%). Compared to controls, PyV encephalitis patients had a significantly higher cumulative incidence of 3‐year NRM (32.0% vs. 13.5%, p = 0.034) and lower 3‐year OS (60.6% vs. 76.6%, p = 0.012). Additionally, PML occurred in 51.8% (28/54) of cases, but no significant differences in NRM or OS compared to non‐PML. In conclusion, PyV encephalitis is associated with poorer clinical outcomes, and BKV/JCV encephalitis exhibit comparable, unfavourable outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Pe…
- Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China.
ORCID-Profile: Xu-Ying Pei, Zhi-Fan Zhao, Yu-Qian Sun, Xiao-Dong Mo, Yu Wang, Lan-Ping Xu, Xiao-Hui Zhang, Xiao-Jun Huang, Meng Lv, Xiang-Yu Zhao
Förderung
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- Being Nova Program
- Beijing Municipal Science & Technology Commission
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park
Zitieren
APA
Pei, X. Y., Yin, X. Y., Sun, H. L., Zhao, Z. F., Ma, L., Wei, F. F., Zhao, X. S., Zhang, Y. Y., Sun, Y. Q., Mo, X. D., Wang, Y., Xu, L. P., Zhang, X. H., Huang, X. J., Lv, M., & Zhao, X. Y. (2025). The clinical features, risk factors and outcomes of polyomavirus encephalitis after allogeneic haematological stem cell transplantation. British Journal of Haematology. https://doi.org/10.1111/bjh.70105
Vancouver
Pei XY, Yin XY, Sun HL, Zhao ZF, Ma L, Wei FF, et al. The clinical features, risk factors and outcomes of polyomavirus encephalitis after allogeneic haematological stem cell transplantation. British Journal of Haematology. 2025. doi:10.1111/bjh.70105
BibTeX
@article{Pei2025,
author = {Pei, Xu-Ying and Yin, Xian-Ying and Sun, Hai-Lu and Zhao, Zhi-Fan and Ma, Ling and Wei, Fang-Fang and Zhao, Xiao-Su and Zhang, Yuan-Yuan and Sun, Yu-Qian and Mo, Xiao-Dong and Wang, Yu and Xu, Lan-Ping and Zhang, Xiao-Hui and Huang, Xiao-Jun and Lv, Meng and Zhao, Xiang-Yu},
title = {The clinical features, risk factors and outcomes of polyomavirus encephalitis after allogeneic haematological stem cell transplantation},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.70105}
}
EUVIMED